JP2022550037A5 - - Google Patents

Info

Publication number
JP2022550037A5
JP2022550037A5 JP2022518772A JP2022518772A JP2022550037A5 JP 2022550037 A5 JP2022550037 A5 JP 2022550037A5 JP 2022518772 A JP2022518772 A JP 2022518772A JP 2022518772 A JP2022518772 A JP 2022518772A JP 2022550037 A5 JP2022550037 A5 JP 2022550037A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
administered
compound
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022518772A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022550037A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/076994 external-priority patent/WO2021058794A1/en
Publication of JP2022550037A publication Critical patent/JP2022550037A/ja
Publication of JP2022550037A5 publication Critical patent/JP2022550037A5/ja
Pending legal-status Critical Current

Links

JP2022518772A 2019-09-25 2020-09-25 局所進行性扁平上皮癌を有する患者の治療のための投与レジメン Pending JP2022550037A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962905703P 2019-09-25 2019-09-25
US62/905,703 2019-09-25
US202063016762P 2020-04-28 2020-04-28
US63/016,762 2020-04-28
EP20184601 2020-07-07
EP20184601.1 2020-07-07
PCT/EP2020/076994 WO2021058794A1 (en) 2019-09-25 2020-09-25 Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma

Publications (2)

Publication Number Publication Date
JP2022550037A JP2022550037A (ja) 2022-11-30
JP2022550037A5 true JP2022550037A5 (cg-RX-API-DMAC7.html) 2023-10-02

Family

ID=72644266

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022518772A Pending JP2022550037A (ja) 2019-09-25 2020-09-25 局所進行性扁平上皮癌を有する患者の治療のための投与レジメン

Country Status (13)

Country Link
US (1) US20250268863A1 (cg-RX-API-DMAC7.html)
EP (1) EP4034102A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022550037A (cg-RX-API-DMAC7.html)
KR (1) KR20220088700A (cg-RX-API-DMAC7.html)
CN (1) CN114727984A (cg-RX-API-DMAC7.html)
AU (1) AU2020356356A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022005624A2 (cg-RX-API-DMAC7.html)
CA (1) CA3151770A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022004947A2 (cg-RX-API-DMAC7.html)
IL (1) IL291682A (cg-RX-API-DMAC7.html)
MX (1) MX2022003628A (cg-RX-API-DMAC7.html)
PH (1) PH12022550721A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021058794A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024022275A1 (zh) * 2022-07-29 2024-02-01 苏州科睿思制药有限公司 Xevinapant的晶型及其制备方法和用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2525585T3 (es) 2006-05-05 2014-12-26 The Regents Of The University Of Michigan Intermedios para la preparación de miméticos de SMAC bivalentes
BRPI0711591A2 (pt) 2006-05-16 2011-11-16 Aegera Therapeutics, Inc. composto de ligação de domìnio bir da iap
WO2008014229A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014240A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
PE20110217A1 (es) 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
WO2008128171A2 (en) * 2007-04-13 2008-10-23 The Regents Of The University Of Michigan Diazo bicyclic smac mimetics and the uses thereof
EP2296650B1 (en) 2008-05-16 2020-05-06 Novartis AG Immunomodulation by iap inhibitors
US20100317593A1 (en) 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
ES2643233T3 (es) 2009-10-23 2017-11-21 The Regents Of The University Of Michigan Miméticos de SMAC bicíclicos diazo bivalentes y los usos de los mismos
EP2493879B1 (en) 2009-10-28 2014-05-14 Joyant Pharmaceuticals, Inc. Dimeric smac mimetics
CA2780130A1 (en) 2009-11-05 2011-05-12 The Uab Research Foundation Treating basal-like genotype cancers
JP2014528409A (ja) 2011-09-30 2014-10-27 テトラロジック ファーマシューティカルズ コーポレーション 増殖性疾患(がん)の治療において使用するためのSMAC模倣体(ビリナパント(birinapant))
US8859541B2 (en) 2012-02-27 2014-10-14 Boehringer Ingelheim International Gmbh 6-alkynylpyridines
AU2013306087B2 (en) 2012-08-23 2017-08-10 The Regents Of The University Of Michigan Bivalent inhibitors of IAP proteins and therapeutic methods using the same
CA2896577C (en) 2012-11-30 2024-01-23 Sanford-Burnham Medical Research Institute Inhibitor of apoptosis protein (iap) antagonists
WO2014121178A1 (en) 2013-02-04 2014-08-07 Tetralogic Pharmaceuticals Corp. Smac mimetic method of treatment
US9278978B2 (en) 2013-08-23 2016-03-08 Boehringer Ingelheim International Gmbh 6-Alkynyl Pyridine
US9249151B2 (en) 2013-08-23 2016-02-02 Boehringer Ingelheim International Gmbh Bis-amido pyridines
CN115368356B (zh) 2013-12-20 2025-05-09 阿斯特克斯治疗有限公司 双环杂环化合物及其治疗用途
AR101479A1 (es) 2014-08-11 2016-12-21 Boehringer Ingelheim Int Derivados de 6-alquinil-piridina
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
AU2015360095B2 (en) * 2014-12-09 2020-02-27 Advenchen Laboratories Nanjing Ltd Quinoline derivative against non-small cell lung cancer
CA2916970A1 (en) 2016-01-08 2017-07-08 Pharmascience Inc. A smac mimetic compound for use in the treatment of proliferative diseases
EP3419643A4 (en) 2016-02-24 2020-04-01 Children's Hospital of Eastern Ontario Research Institute Inc. SMC COMBINATION THERAPY FOR TREATING CANCER
CN110475567A (zh) 2017-03-31 2019-11-19 勃林格殷格翰国际有限公司 抗癌组合疗法
WO2019122941A1 (en) * 2017-12-21 2019-06-27 Debiopharm International Sa Combination anti cancer therapy with an iap antagonist and an anti pd-1 molecule

Similar Documents

Publication Publication Date Title
EP2278960B2 (en) Dosing regimen for a selective sip1 receptor agonist
JP2023088944A5 (cg-RX-API-DMAC7.html)
RU2011139643A (ru) Способ лечения неалкогольного стеатогепатита повышенными дозами урсодезоксихолевой кислоты
JP2010070566A (ja) ウイルス性肝炎の処置
JP2007515469A5 (cg-RX-API-DMAC7.html)
JP2006523216A5 (cg-RX-API-DMAC7.html)
JP2012520866A5 (cg-RX-API-DMAC7.html)
JP2024516363A5 (cg-RX-API-DMAC7.html)
CN107519159A (zh) 复方组合物
JP2023523557A5 (cg-RX-API-DMAC7.html)
JP2023537921A5 (cg-RX-API-DMAC7.html)
JP2024533153A5 (cg-RX-API-DMAC7.html)
JP2006514681A5 (cg-RX-API-DMAC7.html)
JP2022550828A5 (cg-RX-API-DMAC7.html)
WO2017148129A1 (zh) 一种用于治疗恶病质的药物组合物及其应用
JP2025511401A5 (cg-RX-API-DMAC7.html)
JP2025511402A5 (cg-RX-API-DMAC7.html)
JP2024545496A5 (cg-RX-API-DMAC7.html)
JP6370801B2 (ja) 肝疾患または肝障害の治療のための使用および方法
JP2022177119A5 (cg-RX-API-DMAC7.html)
JP2022019937A (ja) ヒト又は動物の慢性若しくは急性のウイルス感染症及び/又は敗血症の予防若しくは治療のための組成物
RU2332227C1 (ru) Способ комплексной терапии больных с плоскоклеточным раком слизистой полости рта
JP2025060703A5 (cg-RX-API-DMAC7.html)
WO1996041643A1 (en) Antiviral method and antiviral agent
JP2023550043A5 (cg-RX-API-DMAC7.html)